- 01 30 manufacturing sites on one platform (Cipla, WEF Global Lighthouse)
- 02 2,500+ concurrent users across all facilities
- 03 Multi-regulatory: FDA, EMA, MHRA, CDSCO on a single MES instance
- 04 10+ facilities digitised globally (Piramal) across 3 regulatory jurisdictions
What FDA Inspectors Cite
Multi-site inspections increasingly compare documentation practices across facilities. These findings show what happens when sites operate inconsistently.
Same product, different documentation standards across sites
Lupin Limited
June 20, 2024
FDA inspectors found that the same product manufactured at two sites produced batch records with different fields, terminology, and data capture methods. No enterprise-wide standard existed, making cross-site quality comparison impossible.
Why Multi-Site Pharma Operates Blind
The problem is not that sites perform poorly in isolation — it is that the manufacturing network cannot see, compare, or coordinate across sites.
Challenge 1/6
Every Site Is a Data Island
- 0110–50+ sites with different systems, formats, and data capture methods
- 02Enterprise-wide quality dashboards are impossible without standardised digital data
- 03The same product at two sites produces records with different fields and terminology
Agentic Architecture
Four specialized AI agents orchestrated by Leucine MES, each with domain-specific skills, enabling real-time network-wide manufacturing intelligence.
Data Layer
Leucine MES
Orchestration Layer
Orchestrates multi-site workflows, manages site configurations, enforces per-jurisdiction regulatory compliance across every action
Quality Outputs
Multi-Site Operations in Leucine MES
1.Single Platform, Multi-Site Architecture
One MES instance deployed across all sites. Not separate installations stitched together — a true multi-tenant architecture where each site has its own configuration but data flows to a unified enterprise layer.
2.Global Production Dashboard
Real-time view of every site's production status: batches in progress, equipment status, line utilisation. The COO sees the entire network on one screen — not individual site reports aggregated weeks later.
3.Cross-Site Scheduling & Capacity Balancing
When Site A has capacity and Site B has a backlog, the system identifies the imbalance. Scheduling considers site capabilities, regulatory status, and product-site qualifications to recommend optimal allocation.
4.Technology Transfer Automation
When a product is validated at one site, the digital MBR can be replicated to another with site-specific equipment mappings and process parameter adaptations — eliminating weeks of manual re-entry.
5.Cross-Site Deviation & CAPA Intelligence
Cortex AI identifies recurring deviation patterns across sites. If Site A and Site C both have yield drops on the same product, the system connects the dots. CAPAs at one site are flagged for propagation to all relevant facilities.
Inputs
Multi-Site Platform
LeucineOS Agent
Outputs
Inputs
Dashboard Engine
LeucineOS Agent
Outputs
Inputs
Scheduling Engine
LeucineOS Agent
Outputs
Inputs
Transfer Engine
LeucineOS Agent
Outputs
Inputs
Cortex Network Intelligence
LeucineOS Agent
Outputs
How Leucine Solves This
Addressing both the operational blind spots that cost millions in underutilised capacity and the compliance gaps FDA finds during multi-site inspections.
One MES Across All Sites — Real-Time, Not Quarterly
A single MES instance spanning all manufacturing sites with site-specific configuration, equipment mapping, and regulatory compliance. Global production dashboard replaces quarterly PowerPoint reports.
Capabilities
- Multi-tenant architecture — one platform, site-specific configurations
- Global production dashboard with real-time batch and equipment status
- Cross-site scheduling with capacity balancing and product-site qualification
- 30 facilities deployed at Cipla — WEF Global Lighthouse designation
Measurable Impact
Real results from pharmaceutical manufacturers running Leucine MES across their global manufacturing networks.
Facilities on One Platform
Manufacturing sites running Leucine MES at Cipla — WEF Global Lighthouse designation
Concurrent Users
Operators, supervisors, and QA staff across all Cipla facilities on a single MES
Regulatory Jurisdictions
FDA, MHRA, and EMA compliance harmonised on one platform across 10+ Piramal sites
Batch Review Time
Reduction — from 20 days to 1 day at Valent BioSciences
Frequently asked questions
How does technology transfer work when moving a validated product between sites?
Once a product is validated at one site, its digital master batch record can be replicated to another with site-specific equipment mappings and process-parameter adaptations, with a full audit trail of every adaptation. That removes the weeks of manual MBR re-entry that cause transfer-related deviations.
Is this one MES instance across all sites, or separate installations stitched together?
One instance with a true multi-tenant architecture. Each site keeps its own configuration and regulatory routing while data flows to a unified enterprise layer, so the network is genuinely comparable rather than a set of local systems reporting upward weeks later.
How does the platform handle different regulators across sites?
Master batch records are authored centrally and deployed per site with locale-specific overrides, and compliance is enforced per jurisdiction on every action. Piramal harmonised FDA, MHRA, and EMA operations across 10 or more sites on one platform.
Can it detect a deviation pattern that spans several sites?
Yes. Cortex correlates deviations across sites, products, and equipment, so a recurring issue at three sites surfaces as one systemic pattern rather than three independent investigations. CAPAs at one site are flagged for propagation to every facility making the same product.
How long does multi-site rollout take compared with a traditional MES?
Traditional MES timelines run 12 to 18 months per site, which turns a 10-site rollout into a multi-year programme. Leucine deploys in weeks per site through configuration, which is how Cipla reached 30 facilities on one platform, recognised by the World Economic Forum as a Global Lighthouse.
Continue exploring
Powered by
Leucine MES
The Manufacturing Execution System for pharmaceutical manufacturing — from digitising batch records with full 21 CFR Part 11 compliance to connecting shop-floor data across a global facility network.
Explore Leucine MESStop managing your manufacturing network through quarterly PowerPoints. Leucine MES gives you real-time visibility across every site — deployed in weeks, not years.